* known allergy to investigational vaccine or its excipients, or previous history of anaphylactic shock or other serious adverse reactions to other vaccines * history of severe acute respiratory syndrome (sars) and/or middle east respiratory syndrome (mers) or covid-19 infection or disease; * used antipyretic drugs, painkillers or anti-allergic drugs within 24 h before enrollment; * vaccination of subunit vaccines and/or inactivated vaccines within 7 days before enrollment, or vaccination of live attenuated vaccines within 14 days before enrollment; * administration of blood or blood related products (including immunoglobulins) within 3 months before enrollment; or plan to use duringthe trial; * patients with the following diseases: 1. any acute disease or in the acute phase of chronic diseases within 7 days before enrollment; 2. congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc.; 3. history of congenital or acquired immunodeficiency or autoimmune diseases, or long-term(used continuously\>14 days)use of glucocorticoid (dose ≥ 20 mg/day prednisone or equivalent dose) or other immunosuppressants within the last 6 months, yet the following situations are allowed to be included: inhaled or topical use of external steroids, or short-term use (course ≤ 14 days ) of oral corticosteroids; 4. positive for anti-aids antibody; 5. neurological diseases or family history (convulsion, epilepsy, encephalopathy, etc.); history of psychosis or family history; 6. asplenia or functional asplenia; 7. serious or uncontrollable cardiovascular diseases, diabetes,hematological and lymphatic diseases, immune system diseases,liver and kidney diseases, respiratory diseases, metabolism and bone diseases, or malignant tumors that need hospitalization; 8. contraindications of intramuscular injection and blood drawing,such as coagulation dysfunction, thrombosis or hemorrhagic diseases, or any condition that needs continuous use of anticoagulant; 9. severe hypertension with uncontrolled medication (at field measurement: systolic blood pressure ≥160mmhg and/or diastolic blood pressure ≥100mmhg) . * history of major surgery within 12 weeks before enrollment (judged by the investigator), or incomplete recovery after surgery, or planning major surgery during the trial; * participating or will participate other clinical trials during this trial; * any disease or condition that would pose an unacceptable risk to the subject; the subject is unable to meet the protocol requirement; will interfere with evaluation of investigational vaccine. * women who were breastfeeding or pregnant during the clinical study or planned to become pregnant during the study;

* known allergy to investigational vaccine or its excipients, or previous history of anaphylactic shock or other serious adverse reactions to other vaccines * history of severe acute respiratory syndrome (sars) and/or middle east respiratory syndrome (mers) or covid-19 infection or disease; * used antipyretic drugs, painkillers or anti-allergic drugs within 24 h before enrollment; * vaccination of subunit vaccines and/or inactivated vaccines within 7 days before enrollment, or vaccination of live attenuated vaccines within 14 days before enrollment; * administration of blood or blood related products (including immunoglobulins) within 3 months before enrollment; or plan to use duringthe trial; * patients with the following diseases: 1. any acute disease or in the acute phase of chronic diseases within 7 days before enrollment; 2. congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc.; 3. history of congenital or acquired immunodeficiency or autoimmune diseases, or long-term(used continuously\>14 days)use of glucocorticoid (dose ≥ 20 mg/day prednisone or equivalent dose) or other immunosuppressants within the last 6 months, yet the following situations are allowed to be included: inhaled or topical use of external steroids, or short-term use (course ≤ 14 days ) of oral corticosteroids; 4. positive for anti-aids antibody; 5. neurological diseases or family history (convulsion, epilepsy, encephalopathy, etc.); history of psychosis or family history; 6. asplenia or functional asplenia; 7. serious or uncontrollable cardiovascular diseases, diabetes,hematological and lymphatic diseases, immune system diseases,liver and kidney diseases, respiratory diseases, metabolism and bone diseases, or malignant tumors that need hospitalization; 8. contraindications of intramuscular injection and blood drawing,such as coagulation dysfunction, thrombosis or hemorrhagic diseases, or any condition that needs continuous use of anticoagulant; 9. severe hypertension with uncontrolled medication (at field measurement: systolic blood pressure ≥160mmhg and/or diastolic blood pressure ≥100mmhg) . * history of major surgery within 12 weeks before enrollment (judged by the investigator), or incomplete recovery after surgery, or planning major surgery during the trial; * participating or will participate other clinical trials during this trial; * any disease or condition that would pose an unacceptable risk to the subject; the subject is unable to meet the protocol requirement; will interfere with evaluation of investigational vaccine. * women who were breastfeeding or pregnant during the clinical study or planned to become pregnant during the study;

known allergy to investigational vaccine or its excipients, or previous history of anaphylactic shock or other serious adverse reactions to other vaccines history of severe acute respiratory syndrome (sars) and/or middle east respiratory syndrome (mers) or covid-19 infection or disease; used antipyretic drugs, painkillers or anti-allergic drugs within 24 h before enrollment; vaccination of subunit vaccines and/or inactivated vaccines within 7 days before enrollment, or vaccination of live attenuated vaccines within 14 days before enrollment; administration of blood or blood related products (including immunoglobulins) within 3 months before enrollment; or plan to use duringthe trial; patients with the following diseases: any acute disease or in the acute phase of chronic diseases within 7 days before enrollment; congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc.; history of congenital or acquired immunodeficiency or autoimmune diseases, or long-term(used continuously>14 days)use of glucocorticoid (dose ≥ 20 mg/day prednisone or equivalent dose) or other immunosuppressants within the last 6 months, yet the following situations are allowed to be included: inhaled or topical use of external steroids, or short-term use (course ≤ 14 days ) of oral corticosteroids; positive for anti-aids antibody; neurological diseases or family history (convulsion, epilepsy, encephalopathy, etc.); history of psychosis or family history; asplenia or functional asplenia; serious or uncontrollable cardiovascular diseases, diabetes,hematological and lymphatic diseases, immune system diseases,liver and kidney diseases, respiratory diseases, metabolism and bone diseases, or malignant tumors that need hospitalization; contraindications of intramuscular injection and blood drawing,such as coagulation dysfunction, thrombosis or hemorrhagic diseases, or any condition that needs continuous use of anticoagulant; severe hypertension with uncontrolled medication (at field measurement: systolic blood pressure ≥160mmhg and/or diastolic blood pressure ≥100mmhg) . history of major surgery within 12 weeks before enrollment (judged by the investigator), or incomplete recovery after surgery, or planning major surgery during the trial; participating or will participate other clinical trials during this trial; any disease or condition that would pose an unacceptable risk to the subject; the subject is unable to meet the protocol requirement; will interfere with evaluation of investigational vaccine. women who were breastfeeding or pregnant during the clinical study or planned to become pregnant during the study;

known allergy to investigational vaccine or its excipients, or previous history of anaphylactic shock or other serious adverse reactions to other vaccines history of severe acute respiratory syndrome (sars) and/or middle east respiratory syndrome (mers) or covid-19 infection or disease; used antipyretic drugs, painkillers or anti-allergic drugs within 24 h before enrollment; vaccination of subunit vaccines and/or inactivated vaccines within 7 days before enrollment, or vaccination of live attenuated vaccines within 14 days before enrollment; administration of blood or blood related products (including immunoglobulins) within 3 months before enrollment; or plan to use duringthe trial; patients with the following diseases: any acute disease or in the acute phase of chronic diseases within 7 days before enrollment; congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc.; history of congenital or acquired immunodeficiency or autoimmune diseases, or long-term(used continuously>14 days)use of glucocorticoid (dose ≥ 20 mg/day prednisone or equivalent dose) or other immunosuppressants within the last 6 months, yet the following situations are allowed to be included: inhaled or topical use of external steroids, or short-term use (course ≤ 14 days ) of oral corticosteroids; positive for anti-aids antibody; neurological diseases or family history (convulsion, epilepsy, encephalopathy, etc.); history of psychosis or family history; asplenia or functional asplenia; serious or uncontrollable cardiovascular diseases, diabetes,hematological and lymphatic diseases, immune system diseases,liver and kidney diseases, respiratory diseases, metabolism and bone diseases, or malignant tumors that need hospitalization; contraindications of intramuscular injection and blood drawing,such as coagulation dysfunction, thrombosis or hemorrhagic diseases, or any condition that needs continuous use of anticoagulant; severe hypertension with uncontrolled medication (at field measurement: systolic blood pressure ≥160mmhg and/or diastolic blood pressure ≥100mmhg) . history of major surgery within 12 weeks before enrollment (judged by the investigator), or incomplete recovery after surgery, or planning major surgery during the trial; participating or will participate other clinical trials during this trial; any disease or condition that would pose an unacceptable risk to the subject; the subject is unable to meet the protocol requirement; will interfere with evaluation of investigational vaccine. women who were breastfeeding or pregnant during the clinical study or planned to become pregnant during the study;